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An immune-suppressive role of myeloid-derived suppressor cells (MDSCs) in
melanoma has long been speculated, whereas molecular mechanisms under-
lying this role are not well understood. Here, Chung and colleagues show that
dendritic cell-associated, heparan sulfate proteoglycans-dependent integrin ligand
(DC-HIL), a cell surface immune-modulatory molecule, is highly expressed on
tumor-associated MDSCs. Genetic ablation or antibody blockade of DC-HIL
delays the growth of transplantable B16 melanoma in syngeneic mice, which is
accompanied by enhanced antitumor T-cell activities. These findings support a
role for DC-HIL in immune evasion within the melanoma microenvironment.
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Recent breakthroughs in the treatment of
a broad spectrum of human metastatic
solid tumors, including melanoma,
through blockade of the PD-1/PD-L1
(B7-H1) immune-suppressive path-
way represents a major conceptual
advancement in cancer immunotherapy.
Different from systemic enhancement
of immune responses with immune-
checkpoint blockade by anti-CTLA-4,
selective modulation of the tumor
microenvironment (TME) by blocking
the interaction between PD-1 on effector
T cells and PD-L1 on tumor cells
and other TME cells can eliminate
large clinically terminal-stage tumors
and metastases with significantly greater
clinical benefit and minimal auto-
immune toxicity (Brahmer et al., 2012;
Topalian et al., 2012). Therefore, under-
standing the molecular mechanisms that
suppress immune responses selectively
within the TME could be important
for the optimal design of therapeutic
interventions.
In addition to tumor cells and host
stromal cells, the TME is also populated
by various blood-derived immune cells,
including MDSCs, that exhibit potent
immune-suppressive activities. Tumor-
induced granulocytic hyperplasia
accompanying immune suppression
was described more than half a century
ago. However, the concept that MDSCs
may reflect the abnormal nature of
myelopoiesis in cancer has only been
well received recently. MDSCs are
highly heterogenic cells with immature
and progenitor-like features of myeloid
origin (Talmadge and Gabrilovich,
2013). These cell types are present
in many patients with cancer and in
animal tumor models, where they sup-
press immune responses on T cells and
other tumor-reactive immune cells pro-
foundly. Furthermore, other studies have
revealed that the number of circulating
MDSCs correlates poorly with cancer
prognosis and that it correlates inversely
with T-cell frequency in melanoma.
Increases in the MDSC population
depend on both tumor burden and
on tumor-secreted factors that regulate
myeloid progenitor cell survival and
expansion. Several factors that may
regulate MSDC accumulation and acti-
vities include the chemokines CCL2 and
CXCL12 and proinflammatory medi-
ators, such as GM-CSF, G-CSF, IL-1b,
IL-6, and prostaglandin E2, as has
been reported recently. Nevertheless,
the mechanisms responsible for the sup-
pressive function MDSCs remain uncer-
tain, although L-arginine metabolism
and reactive oxygen species production
have been attributed to this effect. More-
over, several studies indicate that the
suppressive activities of MDSCs for
T cells, or natural killer cells, are
contact-dependent, possibly requiring
molecular crosstalk between MDSCs
and immune effector cells (Talmadge
and Gabrilovich, 2013).
Dendritic cell-associated, heparan
sulfate proteoglycans (HSPG)-dependent
integrin ligand (DC-HIL), also known as
GPNMB, was identified originally using
subtractive cDNA cloning by comparing
human melanoma lines with high and
low metastatic potential (Weterman
et al., 1995). The DC-HIL gene encodes
a transmembrane protein of 560 amino
acids that displays high homology with
the melanocyte antigen PMEL, and it
may be associated with melanoma
metastasis. Subsequently, another group
cloned the same gene independently,
as a mouse DC-specific protein with
the capacity to bind endothelial cells
in a HSPG-dependent manner. As this
protein also contains an integrin ligand–
like RGD domain, it was named DC-HIL
(Shikano et al., 2001). DC-HIL could
suppress T-cell responses in vitro, and
infusion of soluble DC-HIL protein
exacerbated T-cell responses to antigens
in a mouse model of contact hypersensi-
tivity (Chung et al., 2007b). This effect
was found to be mediated via binding to
syndecan-4 (SDC-4), one of the HSPGs,
on T cells. Cross-linking of SDC-4 by
antibodies also attenuated anti-CD3-
induced T-cell responses in vitro. In
contrast, ablation of SDC-4 by specific
antibodies, knockdown of SDC-4, or
treatment with soluble SDC-4 led to an
enhanced T-cell response to antigen, in a
DC-HIL-dependent manner, and in both
human and mouse systems (Chung et al.,
2007a; 2009). Importantly, by knocking
down DC-HIL in a B16-F10 melanoma
cell line, Tomihari et al. (2010) showed
that melanoma-associated DC-HIL could
inhibit melanoma-reactive T cells and
promote tumor growth in vivo, and in
an SDC-4-dependent manner. However,
the role of DC-HIL in non-melanoma
cells remains uncertain. In this issue of
JID (Chung et al., 2014), further evidence
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demonstrates another mechanism of
action: DC-HIL on MDSCs in the mela-
noma microenvironment may suppress
T-cell responses via SDC-4 (Figure 1).
Therefore, DC-HIL may have a much
broader role than previously thought in
suppressing melanoma immunity in the
microenvironment.
In their article, Chung et al. (2014)
demonstrate that DC-HIL has an
indispensable role in MDSCs’ T cell–
suppressive function in the melanoma
microenvironment. Using a DC-HIL-
deficient B16 tumor cell, they found
that these tumors regressed more rapidly
in DC-HIL knockout versus wild-type
mice. These data suggest that DC-HIL
expression on host cells, but not on
melanoma cells, has an important role
in immune invasion. The authors also
found that DC-HIL was overexpressed
on CD11bþ Gr-1þ myeloid cells,
either in the bone marrow, blood, and
spleen or at the tumor site. Interestingly,
CD11bþ Gr-1þ cells from tumor-free
mice expressed little DC-HIL, suggesting
a tumor-induced phenotype for DC-HIL
expression. DC-HIL-rich CD11bþ Gr-1þ
cells, but not F4/80þ macrophages
or CD11cþ DCs, showed potent
immune-suppressive activities, resem-
bling the phenotype of MDSCs. In addi-
tion, 40% of splenic CD11bþGr-1þ
cells expressed DC-HIL, whereas B20
and B70% of these cells were positive
for PD-L1 or CD80/CD86, respectively.
Although several reports suggest possi-
ble roles for PD-L1 or CD80/86 in
MDSC function, Chung et al. (2014)
found that infusion of DC-HIL anti-
bodies to block the DC-HIL/SDC-4
interaction restored T-cell activities in
an MSDC and T-cell coculture system;
this was not the case when anti-PD-L1
or anti-CD80/86 antibodies were used.
Consistent with these findings, DC-HIL-
deficient myeloid cells failed to suppress
antitumor T-cell responses both in vitro
and in vivo. Therefore, DC-HIL may be
a critical molecule that mediates the
suppressive activities of MSDCs.
With various blocking agents, Chung
et al. (2014) discovered a critical role
for inducible nitric oxide synthase in
the T-cell suppression activities of
DC-HILþ MDSCs. Interestingly, they
also found that blocking IFN-g, but not
IL-10 or transforming growth factor-b,
reversed almost completely the inhibi-
tory effect of MDSCs in a T-cell proli-
feration assay. These data are contradic-
tory to a recent report, which suggested
a minimal role for IFN-g and IL-4R in
MDSC differentiation and function in
several mouse tumor models, including
B16 melanoma (Sinha et al., 2012). This
contradiction may be attributed to the
different roles for IFN-g in the periphery
versus the TME, wherein IFN-g may
induce specific gene products selec-
tively. Although IFN-g is an essential
cytokine in augmenting immune res-
ponses, including the upregulation of
major histocompatibility complexes,
and stimulation of antigen processing
and presentation, IFN-g is also shown to
be a major cytokine responsible for
upregulating the co-inhibitory molecule
PD-L1 in the TME (Sznol and Chen,
2013). Therefore, DC-HIL may be
another suppressor molecule, induced
by IFN-g in the melanoma micro-
environment.
One of the most interesting aspects
of this study is the therapeutic potential
of this pathway as a target in mela-
noma immunotherapy. Currently, it is
not known how broad DC-HIL expres-
sion is in human cancer. Administration
of anti-DC-HIL antibodies markedly
suppresses melanoma growth and
prevents the expansion of CD11bþ
myeloid cells in mice. As DC-HIL
has minimal expression on CD11bþ
Clinical Implications
 The expression of dendritic cell-associated, heparan sulfate proteoglycans-
dependent integrin ligand (DC-HIL) on myeloid-derived suppressor cells
(MDSCs) may contribute to immune suppression in the melanoma
microenvironment.
 Therapeutic blockade of the interaction between DC-HIL and its counter-
receptor syndecan-4 (SDC-4) is a promising, novel approach to enhancing
melanoma immunity.
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Figure 1. Critical role of DC-HIL expression on myelomonocytic cells in melanoma growth. B16-F10
melanoma could induce significant expansion of CD11bþ Gr-1þ myeloid-derived suppressor cells
(MDSCs) in vivo, possible through GM-CSF or IL-4 from tumor or tumor-associated microenvironment.
Concurrently, large amounts of IL-1b and IFN-g are secreted by tumor stromal cells or other immune cells,
resulting in the upregulation of DC-HIL on MDSCs. Upon ligation of DC-HIL counter-receptor SDC-4 on
T cells, DC-HIL itself delivers an important signal to MDSCs, inducing IFN-g, as well as iNOS, thus
inhibiting T-cell responses and promoting tumor growth. DC-HIL, dendritic cell-associated, heparan sulfate
proteoglycans-dependent integrin ligand; iNOS, inducible nitric oxide synthase; NO, nitric oxide;
SDC-4, syndecan-4.
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Gr-1þ cells from tumor-free mice,
factors from melanoma and/or the mela-
noma microenvironment could be
responsible for the selective expression
of DC-HIL in melanoma and in MDSCs.
The authors determined that IL-1b and
IFN-g, which were elevated in the B16-
bearing mouse sera, could trigger DC-HIL
expression synergistically. However,
DC-HIL knockout mice showed similar
kinetics of tumor growth compared
with wild-type mice in EL-4 lymphoma
and LL-2 lung carcinoma. Furthermore,
MDSCs from these tumors did not show
significant upregulation of DC-HIL and
indeed demonstrated less suppressive
activities. These observations, although
implicating melanoma-specific mechan-
isms to promote DC-HIL expression and
to foster MDSC functions, does not
necessarily rule out a broader mechanism
of action in other types of cancer.
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Newly Discovered Olfactory
Receptors in Epidermal Keratinocytes
Are Associated with Proliferation,
Migration, and Re-Epithelialization of
Keratinocytes
Mitsuhiro Denda1,2
Skin contains receptors for various environmental factors. In this issue of the
Journal, Busse et al. cloned a new olfactory receptor, OR2AT4, in keratinocytes.
They show that the activation of OR2AT4 induces phosphorylation of extracellular
signal–regulated kinases and p38 mitogen–activated protein kinases, and that it
accelerates wound healing. OR2AT4 may be a promising candidate as a target in
clinical drug development.
Journal of Investigative Dermatology (2014) 134, 2677–2679. doi:10.1038/jid.2014.229
It is conceivable that chemoreceptor
systems may have been present on the
surface of the body early in the evolu-
tion of multicellular animals, because
present-day invertebrates such as coe-
lenterates, which originated during the
pre-Cambrian period, have sensory and
neural systems distributed throughout
their bodies. Indeed, some vertebrates
retain chemical receptors on their skin
until they enter terrestrial life. For exam-
ple, the odorant receptor family gene
OR2Z4 is not expressed in adult frog
skin, but it is expressed in larval skin
(Amano and Gascuel, 2012). Thus, odo-
rant receptors may have been expressed
extensively on the skin surfaces of aquatic
animals, but subsequently they may have
been concentrated in olfactory cavities,
after the animals had adapted to terre-
strial life. In this scenario, it would not be
surprising to find that some odorant and
chemical receptors are still expressed in
the skin of mammals. If so, would they
retain functional roles?
We demonstrated previously that mul-
tiple transient receptor potential (TRP)
channels are expressed in epidermal
keratinocytes of mice and humans
(Denda and Tsutsumi, 2011). We pro-
posed that they formed part of a sensory
system for physical and chemical factors
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